Past CureTalks
Post-Transplant Outcomes in High Risk Multiple Myeloma
Treatment of patients with myeloma has changed dramatically in the past years due to development of new agents and myeloma specific targets. Despite these advancements, long term benefits remains less clear in high-risk multiple myeloma patients. Myeloma is classified as…
Multidisciplinary Care of Melanoma (Skin Cancer)
No one knows your skin better than you do and you will be the first to notice any changes happening to it. Melanoma is one of the most common cancers in the US. Our Melanoma panel led by David Stanley…
Demystifying Palliative Care (Supportive Care)
Palliative care is often confused with hospice. Very few people are aware that palliative care deals with the quality of life of patients who have a life threatening disease. This would include psychological, social problems in addition to preventing or…
Understanding iSTOPMM: Iceland Screens, Treats, or Prevents Multiple Myeloma with Dr. Sigurour Yngvi Kristinsson
iStopMM initiative may be one of most important events in modern day myeloma care. As part of the iStopMM study, 140,000 Icelanders over the age of 40 will have their blood samples tested for the precursor to multiple myeloma, or…
History and Future Initiatives for High Risk Smoldering Myeloma Cure
For this second talk in our high risk smoldering myeloma series, we have Prof. Jesus San Miguel from University of Navarra, Spain discuss his team's investigations into high-risk smoldering myeloma and probable cure. For patients with smoldering multiple myeloma, the…